CinPhloro Pharma, A CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D
![Cinphloro clinical trial IBS-D](https://cinrx.com/wp-content/uploads/2024/02/web-tile-500x200-cinphloro-1.png)
CinPhloro Pharma Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D.
CinPhloro Pharma Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D.